Portfolio

Active

Abcuro

Abcuro’s mission is to develop a new generation of immunomodulatory therapeutics for treating both autoimmunity and cancer. The company uses proprietary analysis of transcriptome data from human disease to identify new approaches to target key compartments of the immune system. Abcuro was launched in 2016 and is based in Newton, Massachusetts.

Abcuro

Abcuro’s mission is to develop a new generation of immunomodulatory therapeutics for treating both autoimmunity and cancer. The company uses proprietary analysis of transcriptome data from human disease to identify new approaches to target key compartments of the immune system. Abcuro was launched in 2016 and is based in Newton, Massachusetts.

Abcuro website

CytoImmune Therapeutics

CytoImmune Therapeutics is a clinical-stage cancer immunotherapy company focused on the development and commercialization of novel NK cell therapies that can be infused into patients to eliminate cancer cells. The firm is currently developing proprietary Chimeric Antigen Receptor (CAR)-engineered NK cells (CAR-NK™), which represent an off-the-shelf cell therapy designed to destroy tumor cells by recognizing specific proteins or antigens that are present on the tumor surface.

CytoImmune Therapeutics

CytoImmune Therapeutics is a clinical-stage cancer immunotherapy company focused on the development and commercialization of novel NK cell therapies that can be infused into patients to eliminate cancer cells. The firm is currently developing proprietary Chimeric Antigen Receptor (CAR)-engineered NK cells (CAR-NK™), which represent an off-the-shelf cell therapy designed to destroy tumor cells by recognizing specific proteins or antigens that are present on the tumor surface.

CytoImmune Therapeutics website

Dynamic Cell Therapies

Dynamic Cell Therapies (DCT) is preclinical biotech company founded in 2020 out of the Dana Farber Cancer Institute (DFCI) with two platforms to improve and prolong the efficacy of CAR-T therapies.

The company has generated promising results in both in vitro and in vivo multiple myeloma models.

Dynamic Cell Therapies

Dynamic Cell Therapies (DCT) is preclinical biotech company founded in 2020 out of the Dana Farber Cancer Institute (DFCI) with two platforms to improve and prolong the efficacy of CAR-T therapies.

The company has generated promising results in both in vitro and in vivo multiple myeloma models.

Dynamic Cell Therapies (DCT) website

Envisagenics

Envisagenics is an AI-driven biotechnology company founded in 2014 as a spin-out from the Cold Spring Harbor Laboratory that harnesses the therapeutic potential of RNA splicing.

Alternative splicing holds the key to understanding and targeting over 370 diseases, including cancer and neurodegenerative disorders.

Leveraging an extensive map of over 14 million RNA splicing events, Envisagenics’ SpliceCore platform enables the discovery of disease-specific targets, paving the way for the rational design and development of RNA therapeutics and immunotherapies.

Envisagenics currently has 8 programs focused on various cancer and disease indications, including Multiple Myeloma and other hematologic malignancies and has entered into multiple Pharma research collaborations.

Envisagenics

Envisagenics is an AI-driven biotechnology company founded in 2014 as a spin-out from the Cold Spring Harbor Laboratory that harnesses the therapeutic potential of RNA splicing.

Alternative splicing holds the key to understanding and targeting over 370 diseases, including cancer and neurodegenerative disorders.

Leveraging an extensive map of over 14 million RNA splicing events, Envisagenics’ SpliceCore platform enables the discovery of disease-specific targets, paving the way for the rational design and development of RNA therapeutics and immunotherapies.

Envisagenics currently has 8 programs focused on various cancer and disease indications, including Multiple Myeloma and other hematologic malignancies and has entered into multiple Pharma research collaborations.

Envisagenics website

Fortis Therapeutics

Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D. Fortis is located in COI Pharmaceuticals, Avalon’s Community of Innovation, in San Diego.

Fortis Therapeutics

Fortis Therapeutics is an immuno-oncology biotech developing a novel antibody-drug conjugate for late-stage multiple myeloma and metastatic castration-resistant prostate cancer. Fortis was founded based on technology exclusively licensed from UCSF and developed in the laboratory of Bin Liu, Ph.D. Fortis is located in COI Pharmaceuticals, Avalon’s Community of Innovation, in San Diego.

Fortis Therapeutics website

Indapta Therapeutics

Indapta Therapeutics, Inc. is a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. Headquartered in San Francisco, Indapta was founded in 2017 by Guy DiPierro along with Ronald Martell and scientists at the University of California, Davis, and Stanford University. The company has developed allogeneic FcRIγ-deficient natural killer cells, known as G-NK cells, and is working to bring this off-the-shelf cell therapy to patients to address the limitations of currently available autologous T-cell therapies.

Indapta Therapeutics

Indapta Therapeutics, Inc. is a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. Headquartered in San Francisco, Indapta was founded in 2017 by Guy DiPierro along with Ronald Martell and scientists at the University of California, Davis, and Stanford University. The company has developed allogeneic FcRIγ-deficient natural killer cells, known as G-NK cells, and is working to bring this off-the-shelf cell therapy to patients to address the limitations of currently available autologous T-cell therapies.

Indapta Therapeutics website

KAHR

KAHR develops novel dual-targeting fusion protein therapeutics engineered to activate both the innate and the adaptive immune systems simultaneously and localize that response in the tumor microenvironment. KAHR’s lead product candidate, DSP107, is a CD47x41BB targeting compound. DSP107 is being tested in a Phase I/II clinical trial in advanced solid tumors and a Phase 1b clinical trial in blood cancers. KAHR’s preclinical pipeline includes DSP502, a PVRxPD-L1 targeting fusion protein, and DSP216, an HLA-GxCD47 targeting fusion protein.

KAHR

KAHR develops novel dual-targeting fusion protein therapeutics engineered to activate both the innate and the adaptive immune systems simultaneously and localize that response in the tumor microenvironment. KAHR’s lead product candidate, DSP107, is a CD47x41BB targeting compound. DSP107 is being tested in a Phase I/II clinical trial in advanced solid tumors and a Phase 1b clinical trial in blood cancers. KAHR’s preclinical pipeline includes DSP502, a PVRxPD-L1 targeting fusion protein, and DSP216, an HLA-GxCD47 targeting fusion protein.

Kahr website

Luminary Therapeutics

Luminary Therapeutics is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell dysfunction. Luminary was founded by the team from B-MoGen, which was acquired by Bio-Techne in 2019.

Luminary Therapeutics

Luminary Therapeutics is a clinical-stage allogeneic cell therapy company focused on combining advanced receptor design with superior cell engineering to overcome antigen escape and T cell dysfunction. Luminary was founded by the team from B-MoGen, which was acquired by Bio-Techne in 2019.

Luminary Therapeutics website

Nectin Therapeutics

Nectin Therapeutics is a biotechnology company aiming to transform the lives of cancer patients by leveraging its unique insights into the nectin pathway to develop the next generation of immune oncology (IO) therapies. The company’s differentiated therapies have the potential to achieve new standards for efficacy and patient response across a number of difficult-to-treat cancers.

Nectin Therapeutics

Nectin Therapeutics is a biotechnology company aiming to transform the lives of cancer patients by leveraging its unique insights into the nectin pathway to develop the next generation of immune oncology (IO) therapies. The company’s differentiated therapies have the potential to achieve new standards for efficacy and patient response across a number of difficult-to-treat cancers.

Nectin Therapeutics website

Opna Bio

Opna Bio is a clinical stage, oncology-focused company.

Founded to develop drugs against new cancer targets (fragile-X mental retardation protein (FMRP)), Opna acquired several drug development projects from Plexxikon in March 2023, including the current lead asset, an EP300/CBP inhibitor and 3 additional programs.

Opna’s lead program OPN-6602 is an oral daily dual EP300/CBP inhibitor with best-in-class potential (it had been selected jointly by originators Daiichi Sankyo & Plexxikon).

It has been granted Fast Track Designation and Orphan Drug Designation by the US FDA, which also recently approved the IND so that the phase 1 study can proceed.

In 2027, the plan is to initiate a phase 2 study for accelerated approval.

Opna Bio

Opna Bio is a clinical stage, oncology-focused company.

Founded to develop drugs against new cancer targets (fragile-X mental retardation protein (FMRP)), Opna acquired several drug development projects from Plexxikon in March 2023, including the current lead asset, an EP300/CBP inhibitor and 3 additional programs.

Opna’s lead program OPN-6602 is an oral daily dual EP300/CBP inhibitor with best-in-class potential (it had been selected jointly by originators Daiichi Sankyo & Plexxikon).

It has been granted Fast Track Designation and Orphan Drug Designation by the US FDA, which also recently approved the IND so that the phase 1 study can proceed.

In 2027, the plan is to initiate a phase 2 study for accelerated approval.

Opna Bio website

Reverb Therapeutics

Reverb is a seed-stage oncology company with a highly differentiated platform approach to cytokine therapy. Its Amplifier™ platform uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokines. Instead of using heavily engineered exogenous cytokines to treat diseases, which present challenges such as systemic toxicity and immunogenicity, Reverb’s antibodies redirect endogenous cytokines already in the body to cells of interest.

Reverb Therapeutics

Reverb is a seed-stage oncology company with a highly differentiated platform approach to cytokine therapy. Its Amplifier™ platform uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokines. Instead of using heavily engineered exogenous cytokines to treat diseases, which present challenges such as systemic toxicity and immunogenicity, Reverb’s antibodies redirect endogenous cytokines already in the body to cells of interest.

Reverb Therapeutics website

Telo Therapeutics

Telo Therapeutics is developing orally bioavailable next generation inhibitors of nuclear transport, a critical nexus among many cancer cell signaling pathways. The company’s unique chemistry and distinct mechanism of action result in a favorable safety profile and lead to rapid tumor regressions across animal models of multiple cancer types. Telo has generated durable complete responses with just two weeks of dosing in xenografts of both multiple myeloma and glioblastoma.

Telo Therapeutics

Telo Therapeutics is developing orally bioavailable next generation inhibitors of nuclear transport, a critical nexus among many cancer cell signaling pathways. The company’s unique chemistry and distinct mechanism of action result in a favorable safety profile and lead to rapid tumor regressions across animal models of multiple cancer types. Telo has generated durable complete responses with just two weeks of dosing in xenografts of both multiple myeloma and glioblastoma.

Telo Therapeutics website

Triumvira Immunologics

Triumvira Immunologics is a clinical-stage company developing non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology is a versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. The lead program, TAC01-HER2, is currently being evaluated in a Phase 1/2 clinical trial for patients with HER2-overexpressing solid tumors (TACTIC-2), including breast, gastric, ovarian, pancreatic, gall bladder and non-small cell lung cancers.

Triumvira Immunologics

Triumvira Immunologics is a clinical-stage company developing non-gene edited, first-in-class targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors. The company’s proprietary T cell Antigen Coupler (TAC) technology is a versatile platform that activates natural T cell functions differently from cell therapies such as CAR-T and engineered T cell receptor (TCR) therapies. The lead program, TAC01-HER2, is currently being evaluated in a Phase 1/2 clinical trial for patients with HER2-overexpressing solid tumors (TACTIC-2), including breast, gastric, ovarian, pancreatic, gall bladder and non-small cell lung cancers.

Triumvira Immunologics website

Exited

Cullinan MICA

Cullinan MICA exited the MIF Portfolio on April 12, 2024.

Cullinan MICA

Cullinan MICA exited the MIF Portfolio on April 12, 2024.

Tidal Therapeutics

Tidal Therapeutics was acquired by Sanofi on April 9, 2021.

Tidal Therapeutics

Tidal Therapeutics was acquired by Sanofi on April 9, 2021.

Read Press Release

NexImmune

NexImmune announced pricing of upsized initial public offering on February 11, 2021.

NexImmune

NexImmune announced pricing of upsized initial public offering on February 11, 2021.

Read Press Release

Contact Us

If you would like to contact The Myeloma Investment Fund, please use the email form below, call us at (203) 229 0464, or contact us by regular mail at the following address:

383 Main Avenue, 5th Floor
Norwalk, CT 06851




In order to submit the form please click, “I’m not a robot.”